Meningitis B in Ireland: Current Status and Future Outlook
Nine cases of meningitis B have been confirmed in Ireland so far this year, prompting reassurance from the Health Service Executive (HSE) that there is no evidence of a link to the recent outbreak in Kent, England. While the situation is currently stable, understanding the trends and preventative measures surrounding meningococcal disease is crucial for public health.
Understanding Meningococcal Disease
Meningococcal disease is a serious bacterial infection that can cause meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicaemia (blood poisoning). The bacteria exists in several different serotypes, with type B being particularly prevalent. In Ireland, nine of the twelve reported cases of meningococcal disease in 2026 to date have been serogroup B.
The disease can affect individuals of any age, but poses the greatest risk to babies, young children, and, to a lesser extent, teenagers and young adults. Cases in Ireland typically increase during the winter and early spring months.
Recent Case Numbers and HSE Response
The HSE reports 12 cases of meningococcal disease so far in 2026, with no deaths reported. This compares to 60 cases in 2023 (38 serogroup B) and 66 cases in 2024 (42 serogroup B). Dr. John Cuddihy, HSE National Director for Public Health, emphasized that current activity levels are within expected seasonal norms.
Health officials in the UK have confirmed 15 laboratory-confirmed cases of meningitis B and are investigating a further 12 suspected cases following an outbreak in Kent, where two people have died. However, the HSE has found no indication of a connection between these cases and those in Ireland.
Vaccination Programs in Ireland
Ireland has a robust vaccination program in place to protect against meningococcal disease. The MenB vaccine is included in the free national childhood immunisation schedule for babies born on or after October 1, 2016, administered in three doses at two, four, and 12 months of age.
Dr. Lucy Jessop, Director of the HSE’s National Immunisation Office, highlighted that the MenB vaccine is strategically timed to protect infants under one year old, who are most vulnerable. The MenACWY vaccine, protecting against types A, C, W, and Y, is offered in the first year of secondary school.
Recognizing the Symptoms
Early detection is critical for successful treatment. Symptoms of meningococcal disease can develop rapidly and include:
- Fever
- Severe headache
- Vomiting
- Rapid breathing
- Cold hands and feet
- Drowsiness
- A rash that doesn’t fade under pressure (glass test)
Individuals experiencing these symptoms should seek immediate medical attention.
Future Trends and Considerations
While current vaccination programs are effective, ongoing surveillance and research are essential to monitor the evolving landscape of meningococcal disease. The emergence of latest strains and potential waning immunity necessitate continuous evaluation of vaccination strategies.
The HSE continues routine surveillance, demonstrating that meningococcal disease remains a rare, but serious, infection in Ireland. Maintaining high vaccination rates and public awareness are key to minimizing the risk of outbreaks and protecting vulnerable populations.
Frequently Asked Questions
What is the glass test? The glass test involves pressing a glass against a rash. If the rash doesn’t fade under pressure, it could be a sign of meningococcal disease and requires immediate medical attention.
Who is most at risk of meningitis B? Babies and young children are most at risk, but teenagers and young adults can also be affected.
Is there a catch-up vaccine for older children? Currently, there is no catch-up Men B vaccine program for older children in Ireland.
Where can I find more information about meningitis? Visit the HSE website for comprehensive information on meningitis and vaccination programs: https://www.hse.ie/
What should I do if I suspect someone has meningitis? Seek immediate medical attention. Do not wait for a rash to appear.
